A Pan-cancer Analysis of Thioredoxin-interacting Protein As an Immunological and Prognostic Biomarker

Overview

Journal Cancer Cell Int

Publisher Biomed Central

Date 2022 Jul 17

PMID 35843949

Authors

Xuxue Guo

Mei Huang

Haonan Zhang

Qianhui Chen

Ying Hu

Yan Meng

Changjie Wu

Chenge Tu

Yongfeng Liu

Aimin Li

Qingyuan Li

Peirong Zhou

Side Liu

Affiliations

Soon will be listed here.

Abstract

Background: The critical role of thioredoxin-interacting protein (TXNIP) in cellular sulfhydryl redox homeostasis and inflammasome activation is already widely known, however, no pan-cancer analysis is currently available.

Methods: We thus first explored the potential roles of TXNIP across thirty-three tumors mainly based on The Cancer Genome Atlas and Gene Expression Omnibus datasets.

Results: TXNIP is lowly expressed in most cancers, and distinct associations exist between TXNIP expression and the prognosis of tumor patients. TXNIP expression was associated with tumor mutational burden, microsatellite instability, mismatch repair genes, tumor infiltrating immune cell abundance as well as cancer-associated fibroblasts. Moreover, ubiquitin mediated proteolysis, protein post-translational modification and other related pathways were involved in the functional mechanisms of TXNIP.

Conclusions: Our first pan-cancer study comprehensively revealed the carcinostatic role of TXNIP across different tumors. And this molecule may be considered as a potential immunological and prognostic biomarker.

Citing Articles

Vitamin D Upregulated Protein 1 Deficiency Promotes Azoxymethane/Dextran Sulfate Sodium-Induced Colorectal Carcinogenesis in Mice.

Park K, Kim H, Won Y, Yoon W, Choi I, Han S Cancers (Basel). 2024; 16(17).

PMID: 39272794 PMC: 11394134. DOI: 10.3390/cancers16172934.

The role of TXNIP in cancer: a fine balance between redox, metabolic, and immunological tumor control.

Deng J, Pan T, Liu Z, McCarthy C, Vicencio J, Cao L Br J Cancer. 2023; 129(12):1877-1892.

PMID: 37794178 PMC: 10703902. DOI: 10.1038/s41416-023-02442-4.

References

Furukawa M, He Y, Borchers C, Xiong Y . Targeting of protein ubiquitination by BTB-Cullin 3-Roc1 ubiquitin ligases. Nat Cell Biol. 2003; 5(11):1001-7. DOI: 10.1038/ncb1056. View

Hwang J, Suh H, Jeon Y, Hwang E, Nguyen L, Yeom J . The structural basis for the negative regulation of thioredoxin by thioredoxin-interacting protein. Nat Commun. 2014; 5:2958. PMC: 3941024. DOI: 10.1038/ncomms3958. View

Cilona M, Locatello L, Novelli L, Gallo O . The Mismatch Repair System (MMR) in Head and Neck Carcinogenesis and Its Role in Modulating the Response to Immunotherapy: A Critical Review. Cancers (Basel). 2020; 12(10). PMC: 7602801. DOI: 10.3390/cancers12103006. View

Ashton T, McKenna W, Kunz-Schughart L, Higgins G . Oxidative Phosphorylation as an Emerging Target in Cancer Therapy. Clin Cancer Res. 2018; 24(11):2482-2490. DOI: 10.1158/1078-0432.CCR-17-3070. View

Zhang X, Quan F, Xu J, Xiao Y, Li X, Li Y . Combination of multiple tumor-infiltrating immune cells predicts clinical outcome in colon cancer. Clin Immunol. 2020; 215:108412. DOI: 10.1016/j.clim.2020.108412. View

Aran D, Sirota M, Butte A . Corrigendum: Systematic pan-cancer analysis of tumour purity. Nat Commun. 2016; 7:10707. PMC: 4748227. DOI: 10.1038/ncomms10707. View

Huang D, Sherman B, Lempicki R . Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2008; 37(1):1-13. PMC: 2615629. DOI: 10.1093/nar/gkn923. View

Hu J, Yu Y . The Function of Thioredoxin-Binding Protein-2 (TBP-2) in Different Diseases. Oxid Med Cell Longev. 2018; 2018:4582130. PMC: 5954861. DOI: 10.1155/2018/4582130. View

Tang Z, Kang B, Li C, Chen T, Zhang Z . GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019; 47(W1):W556-W560. PMC: 6602440. DOI: 10.1093/nar/gkz430. View

10.

Mohamed I, Hafez S, Fairaq A, Ergul A, Imig J, El-Remessy A . Thioredoxin-interacting protein is required for endothelial NLRP3 inflammasome activation and cell death in a rat model of high-fat diet. Diabetologia. 2013; 57(2):413-23. PMC: 3947289. DOI: 10.1007/s00125-013-3101-z. View

11.

Nagy A, Lanczky A, Menyhart O, Gyorffy B . Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. Sci Rep. 2018; 8(1):9227. PMC: 6003936. DOI: 10.1038/s41598-018-27521-y. View

12.

Robbins P . Tumor-Infiltrating Lymphocyte Therapy and Neoantigens. Cancer J. 2017; 23(2):138-143. DOI: 10.1097/PPO.0000000000000267. View

13.

Chandrashekar D, Bashel B, Balasubramanya S, Creighton C, Ponce-Rodriguez I, Chakravarthi B . UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia. 2017; 19(8):649-658. PMC: 5516091. DOI: 10.1016/j.neo.2017.05.002. View

14.

Clough E, Barrett T . The Gene Expression Omnibus Database. Methods Mol Biol. 2016; 1418:93-110. PMC: 4944384. DOI: 10.1007/978-1-4939-3578-9_5. View

15.

Spindel O, Burke R, Yan C, Berk B . Thioredoxin-interacting protein is a biomechanical regulator of Src activity: key role in endothelial cell stress fiber formation. Circ Res. 2014; 114(7):1125-32. PMC: 3981969. DOI: 10.1161/CIRCRESAHA.114.301315. View

16.

Le Clorennec C, Lazrek Y, Dubreuil O, Sampaio C, Larbouret C, Lanotte R . ITCH-dependent proteasomal degradation of c-FLIP induced by the anti-HER3 antibody 9F7-F11 promotes DR5/caspase 8-mediated apoptosis of tumor cells. Cell Commun Signal. 2019; 17(1):106. PMC: 6708219. DOI: 10.1186/s12964-019-0413-8. View

17.

Alhawiti N, Al Mahri S, Aziz M, Malik S, Mohammad S . TXNIP in Metabolic Regulation: Physiological Role and Therapeutic Outlook. Curr Drug Targets. 2017; 18(9):1095-1103. PMC: 5543564. DOI: 10.2174/1389450118666170130145514. View

18.

Zhang X, Lan Y, Xu J, Quan F, Zhao E, Deng C . CellMarker: a manually curated resource of cell markers in human and mouse. Nucleic Acids Res. 2018; 47(D1):D721-D728. PMC: 6323899. DOI: 10.1093/nar/gky900. View

19.

Gupta R, Li F, Roszik J, Lizee G . Exploiting Tumor Neoantigens to Target Cancer Evolution: Current Challenges and Promising Therapeutic Approaches. Cancer Discov. 2021; 11(5):1024-1039. PMC: 8102318. DOI: 10.1158/2159-8290.CD-20-1575. View

20.

Blum A, Wang P, Zenklusen J . SnapShot: TCGA-Analyzed Tumors. Cell. 2018; 173(2):530. DOI: 10.1016/j.cell.2018.03.059. View